Schreeb, A. published the artcilePiperazine modification in 2,4,6-triaminopyrimidine derivatives as histamine H4 receptor ligands, Safety of 2-Amino-4,6-dichloropyrimidine, the publication is Pharmazie (2013), 68(7), 521-525, database is CAplus and MEDLINE.
The human histamine H4 receptor (hH4R) is a promising new target in the therapy of inflammatory and immunomodulatory diseases. The 2,4,6-triaminopyrimidine structure has been established as a potent hH4R affinity scaffold. By using the inverse agonist ST-1012 as reference ligand, piperazine modifications were performed to get larger structural variations. Therefore, different spacers were introduced into the lead structure and the influence on affinity of this basic element was evaluated. While a short distance between aminopyrimidine and basic moiety is beneficial, a lipophilic group in the eastern part is necessary to maintain hH4R affinity. The title compounds thus formed included a piperazine pyrimidine indoline derivative (I) and related substances, such as 4,6-bis(4-methyl-1-piperazinyl)-2-pyrimidinamine. The synthesis of the target compounds was achieved by a reaction of 4,6-dichloro-2-pyrimidinamine with 4-methyl-1-piperazineethanamine, 4-methyl-1-piperazinepropanamine, 4-methyl-1-piperazinebutanamine, etc.
Pharmazie published new progress about 56-05-3. 56-05-3 belongs to pyrimidines, auxiliary class Pyrimidine,Chloride,Amine,API, name is 2-Amino-4,6-dichloropyrimidine, and the molecular formula is C4H3Cl2N3, Safety of 2-Amino-4,6-dichloropyrimidine.
Referemce:
https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimidine,
Pyrimidine – Wikipedia